Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Breast Inflammatory Carcinoma
Stage IV Breast Inflammatory Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Cobimetinib
DRUG: Eribulin
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

M.D. Anderson Cancer Center